Enhanced immune surveillance due to MMR inactivation provides an additional opportunity for immunotherapy, of which programmed death-1 (PD-1) inhibitor is more efficient and effective in MMR-deficient CRC patients [40]. Here, MRC1 is linked to colorectal carcinoma.